.jpg "Cantor Fitzgerald Sticks to Its Buy Rating for Dynavax")
In a report released today, Elemer Piros from Cantor Fitzgerald reiterated a Buy rating on Dynavax (NASDAQ: DVAX), with a price target of $27. The company’s shares opened today at $19.35.
Piros commented:
“Dynavax’s approved product, HEPLISAV-B, is a TLR9 agonist (1018 ISS) combined with recombinant Hepatitis surface Antigen (rHBsAg) used to vaccinate adults for the prophylaxis of HBV infection. When compared with existing vaccines, HEPLISAV-B has demonstrated higher protection in general patient groups and in high-risk patient populations, with a significantly more-convenient dosing profile. HEPLISAV-B was approved on November 9, 2017.”
According to TipRanks.com, Piros is a 1-star analyst with an average return of -1.2% and a 52.7% success rate. Piros covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Strongbridge Biopharma Plc, and Global Blood Therapeutics.
Currently, the analyst consensus on Dynavax is Strong Buy and the average price target is $29.80, representing a 54.0% upside.
In a report issued on May 8, Cowen & Co. also maintained a Buy rating on the stock with a $30 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $24.45 and a one-year low of $5.35. Currently, Dynavax has an average volume of 1.65M.
Based on the recent corporate insider activity of 19 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Dynavax Technologies Corp. is a clinical-stage biopharmaceutical company that uses toll-like receptor biology to discover and develop novel vaccines and therapeutics. The company’s development programs are organized under its three areas of focus: vaccine adjuvants, cancer immunotherapy, and autoimmune and inflammatory diseases.
Read More on DVAX:
